“Treating Autism with Bumetanide” - New book co-authored by GNCs Nouchine Hadjikhani -
Summary of new book co-authored by Nouchine Hadjikhani entitled "Treating Autism with Bumetanide"
Despite the widespread occurrence, extensive media attention, and significant clinical impact on families, there is currently no approved drug treatment for Autism Spectrum Disorders (ASDs) in Europe or the United States. Existing genetic and psychiatric approaches to ASD treatment have limitations, prompting the need for a new, comprehensive global approach.
Drawing on the authors' combined expertise in brain development, ASD treatment, and brain imaging, this book presents a fresh perspective on ASD. The insights are supported by experimental imaging and large clinical trials, including the first phase 3 paediatric trial involving 400 children in EU countries and the US. This trial repurposes a long-established hypertension and edema drug.
Unprecedented convergence of experimental and clinical data confirms the potential of this drug as the first paediatric treatment for ASDs. The book delves into the mechanisms of ASDs, highlighting specific cases where children showed significant improvements in sociability and reduced agitation after treatment.
The authors also address skepticism from proponents of pure genetics and psychiatry. They explore how the lack of information on developmental disorders has hindered progress in understanding and treating ASDs.
The results from ongoing open trials at the GNC have been published (Fernell et al 2021) and new studies are currently in completion that support the conclusions drawn by the authors of the book.